Everest Medicines Announces Full Approval of NEFECON® in Taiwan

Approval of NEFECON®: Everest Medicines announced that the Taiwan Food and Drug Administration has approved NEFECON®, a treatment for primary immunoglobulin A nephropathy (IgAN), which helps reduce kidney function loss in adults at risk of disease progression. This approval removes previous requirements for confirmatory trial analysis and confirms NEFECON® as a first-line treatment across Asia.

Clinical Benefits and Accessibility: The approval is based on positive results from the Phase 3 NefIgArd clinical trial, showing significant benefits in kidney function preservation and reduced proteinuria. Everest Medicines aims to enhance accessibility and affordability of NEFECON® to improve the quality of life for IgAN patients throughout Asia.